News

Under the alliance agreement Sanofi-aventis obtains a worldwide exclusive license to develop and commercialize the compounds As part of the research alliance, Sanofi-aventis will work together with Avila

The development candidate, RXI-109, is a self-delivering RNAi compound (sd-rxRNA) that will initially be evaluated for the reduction of dermal scarring in planned surgeries. RXi Pharma said that

The local distributors will sell the China-Biotics’ retail probiotics products through their distribution networks including malls, supermarkets and functional food stores adding approximately 30 new points of sale.

The novel combinations involve Merck Serono‘s MEK inhibitor MSC1936369B (also known as AS703026), Sanofi-aventis PI3K/mTOR inhibitor SAR245409 (also known as XL765) and class I PI3K inhibitor SAR245408 (also

iSOFT Group has moved into the life science space with solutions that extract and de-identify clinical data from electronic medical records for clinical research and other secondary uses

The new funding follows the positive results demonstrated during the OLNORME (Occurrence of novel Ligands for a Nuclear Orphan Receptor in plant Metabolites) programme, initiated in 2006. During

The Scopius-5 database platform stores many details of selected compounds such as: multiple-conformation 3D models, shape and charge descriptors, property values and compound availability information, and/or synthetic route

In addition, 3M has IRMs available for license in the areas of cancer, asthma/allergy and as vaccine adjuvants. 3M Drug Delivery Systems Vaccine Business Development director Mark Tomai

Under the terms of the agreement, Recordati receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East,